Rapid Abstract Session A: Cancers of the Esophagus and Stomach
Marcia Cruz-Correa, MD, PhD—Chair
Abstract 5: Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani, MD
Adjuvant durvalumab in patients with persistent residual disease in the surgical sample following trimodality therapy for LA-EAC and GEJ adenocarcinoma was feasible.
The safety profile of durvalumab was consistent with what has been previously reported.
Efficacy results are encouraging in this high-risk population with 1-yr RFS of 79.2% and projected 26 months RFS of 67.9%.
The study will be expanded to enroll 14 additional patients
Clinical trial information: NCT02639065
Abstract 6: FOLFOX versus POF (Paclitaxel plus FOLFOX) versus IP PAC (Intraperitoneal Paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
First Author: Rongbo Lin
CONCLUSION: Both POF and IP PAC improved survival compared to FOLFOX. Only POF, not IP PAC, improved response rate compared to FOLFOX. Addition with paclitaxel intravenously or intraperitoneally does not increase toxicity significantly. Clinical trial information: NCT02845908
Abstract 7: Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).
First Author: Ken Kato, MD, PhD
Esophagectomy and CRT both showed long term activity and acceptable safety for the patients with stage I ESCC.
CRT showed non-inferiority compared to esophagectomy on overall survival in non-randomized part.
CRT seemed to be one of the standard treatment options for stage 1 ESCC.
Clinical trial information: UMIN000000551
Abstract 8: Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.
First Author: Yoon-Koo Kang, MD, PhD
The results from this analysis suggest that patients with hyponatremia along with high NLR may show low benefit with nivolumab treatment in terms of early progression/death.
Factors suggestive of patient's poor general condition (low sodium) and severe inflammation (high NLR) may be associated with reduced efficacy of nivolumab treatment in patients with advanced G/GEJ cancer.
This analysis had several limitations including this being an exploratory, post-hoc machine learning analysis with a small sample size of the identified subgroup.
As this was an exploratory analysis, results need to be verified further.
Clinical trial information: NCT02267343